Universität zu Köln

Gillentine, Madelyn A., Lozoya, Ricardo, Yin, Jiani, Grochowski, Christopher M., White, Janson J., Schaaf, Christian P. and Calarge, Chadi A. (2018). CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders. J. Affect. Disord., 239. S. 247 - 253. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1573-2517

Full text not available from this repository.

Abstract

Objective: Neuronal nicotinic acetylcholine receptors (nAChRs), specifically the alpha 7 nAChR encoded by the gene CHRNA7, have been implicated in behavior regulation in animal models. In humans, copy number variants (CNVs) of CHRNA7 are found in a range of neuropsychiatric disorders, including mood and anxiety disorders. Here, we aimed to determine the prevalence of CHRNA7 CNVs among adolescents and young adults with major depressive disorder (MDD) and anxiety disorders. Methods: Twelve to 21 year-old participants with MDD and/or anxiety disorders (34% males, mean +/- std age: 18.9 +/- 1.8 years) were assessed for CHRNA7 copy number state using droplet digital PCR (ddPCR) and genomic quantitative PCR (qPCR). Demographic, anthropometric, and clinical data, including the Beck Anxiety Index (BAI), Beck Depression Inventory (BDI), and the Inventory of Depressive Symptoms (IDS) were collected and compared across individuals with and without a CHRNA7 CNV. Results: Of 205 individuals, five (2.4%) were found to carry a CHRNA7 gain, significantly higher than the general population. No CHRNA7 deletions were identified. Clinically, the individuals carrying CHRNA7 duplications did not differ significantly from copy neutral individuals with MDD and/or anxiety disorders. Conclusions: CHRNA7 gains are relatively prevalent among young individuals with MDD and anxiety disorders (odds ratio = 4.032) without apparent distinguishing clinical features. Future studies should examine the therapeutic potential of a7 nAChR targeting drugs to ameliorate depressive and anxiety disorders.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gillentine, Madelyn A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lozoya, Ricardo UNSPECIFIED UNSPECIFIED UNSPECIFIED Yin, Jiani UNSPECIFIED UNSPECIFIED UNSPECIFIED Grochowski, Christopher M. UNSPECIFIED UNSPECIFIED UNSPECIFIED White, Janson J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaaf, Christian P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Calarge, Chadi A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-169344
DOI:	10.1016/j.jad.2018.07.017
Journal or Publication Title:	J. Affect. Disord.
Volume:	239
Page Range:	S. 247 - 253
Date:	2018
Publisher:	ELSEVIER SCIENCE BV
Place of Publication:	AMSTERDAM
ISSN:	1573-2517
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NICOTINIC ACETYLCHOLINE-RECEPTORS; PHASE-2 TRIAL; PHENOTYPES; 15Q13.3; SCHIZOPHRENIA; ACTIVATION; SYMPTOMS; AGONIST; CREB Multiple languages Clinical Neurology; Psychiatry Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/16934